A new AI capability that delivers analysis-ready Media Intelligence. More than just a product launch, this is a shift in how communications teams monitor, understand and act on media coverage.
Welcome to OncoDaily, your daily source for cancer related news, updates, and inspiring stories. Our platform is dedicated to providing valuable information about cancer, highlighting the work of professionals in the field, and fostering a community where individuals can come together to raise awareness and support one another. Source
Reena Morjaria, Head of Research Funding at Bowel Cancer UK, shared a post on LinkedIn: “Final (st)roll of the DiCE? A 5.30am start wasn’t quite what I had in mind… But after spending the last couple of days representing Bowel Cancer UK at the Digestive Cancers Europe Masterclass, alongside patient advocates and organisations from across Europe, it felt only right to round off the event with the DiCE Fun Run and Walk.
Ryan R. Lion, Clinical Fellow in Pediatric Hematology/Oncology at St. Jude Children’s Research Hospital, shared a post on LinkedIn: “An incredible week in Dakar focused on one shared goal: improving outcomes for children with cancer in Sénégal It was a true honor to lead the national PrOFILE workshop in Sénégal alongside an extraordinary group of colleagues and partners hosted by the Ministry of Health and Public Hygiene.
Vandana Mahajan, Palliative Care Counselor, Cancer Counselor, Patient Advocate, and Cancer Survivor, shared a post on LinkedIn: “The LuNGS Alliance is a powerful reminder that Every life matters, irrespective of financial status. The LuNGS Alliance, spearheaded by eminent oncologist Dr. Kumar Prabhash, is a wonderful initiative in clinical collaboration and deep human compassion.
Louise Bach Callesen, MD, PhD at Aarhus University Hospital, shared a post on LinkedIn: “Do methylation- and mutation-based ddPCR assays provide overlapping or complementary information for MRD detection? Today I had the pleasure of presenting our OPTIMISE poster at ESMOGI2026.
UC Davis School of Medicine Office of Research shared a post on LinkedIn: “UC Davis Health has received a prestigious seven-year, $40 million award from the National Institutes of Health (NIH) to continue and expand its Clinical and Translational Science Center (CTSC), a critical bridge between research and patient care. The funding comes from the NIH’s Clinical and Translational Science Awards (CTSA) program.
Samuel Stevens, Common Sense Oncology Fellow in Cancer Policy at Queen’s University and VMO – Medical Oncologist at NSW Health, shared a post on LinkedIn: “As my fellowship with Common Sense Oncology at Queen’s University draws to a close, we leave Kingston with mixed feelings. It has been a tremendously enabling academic environment, full of generous mentorship, great collaborations, and meaningful work.
King Hussein Cancer Foundation and Center shared a post on LinkedIn: “‘Immensely proud of our partnership with the Stavros Niarchos Foundation– a partnership built on a simple belief: every child deserves access to life-saving cancer care, regardless of where they are born. Together, we are proving that international collaboration can turn that belief into reality.'” More posts about KHCF/KHCC.
Katie Coleman, Senior Advisor for Translational Innovation at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn: “Dr. Kimryn Rathmell shared this week, during her installation as a distinguished chair, that when she began her career, patients with metastatic kidney cancer were sent home on hospice. That very same day, I celebrated the 5 year anniversary of the day my prognosis changed.
Dierickx Lawrence, Nuclear Oncology, Coordinator at Institut Universitaire Cancer Toulouse Oncopole, shared a post on LinkedIn: “A tremendous amount of work went into this international multicentre study, and I am very happy to have contributed to this important collaborative effort. The study demonstrates a significant improvement in progression-free survival with 177Lu-edotreotide compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumours.
Union for International Cancer Control shared a post on LinkedIn: “When a cancer can be detected early, at stage 1 or 2, the chances of treating it successfully are higher. In low-and middle-income countries, cancer is often diagnosed at a later stage 3 or 4, when the cancer is no longer localised and has spread to other parts of the body.